Furthermore, these trogocytosed-HER2+ immune effector cells show significantly higher levels of CD107a expression, a marker of target cancer cell cytotoxicity, compared to non-trogocytosed-HER2 immune effector cells. Here, ERBB2 is linked to cancer.